A detailed history of Martingale Asset Management L P transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Martingale Asset Management L P holds 40,163 shares of TRDA stock, worth $331,746. This represents 0.01% of its overall portfolio holdings.

Number of Shares
40,163
Previous 38,623 3.99%
Holding current value
$331,746
Previous $667,000 45.58%
% of portfolio
0.01%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025

BUY
$9.04 - $18.31 $13,921 - $28,197
1,540 Added 3.99%
40,163 $363,000
Q4 2024

Feb 13, 2025

BUY
$15.82 - $21.59 $11,074 - $15,113
700 Added 1.85%
38,623 $667,000
Q3 2024

Nov 14, 2024

BUY
$13.65 - $17.86 $139,584 - $182,636
10,226 Added 36.92%
37,923 $606,000
Q2 2024

Aug 12, 2024

BUY
$11.85 - $16.45 $109,553 - $152,080
9,245 Added 50.1%
27,697 $394,000
Q1 2024

May 14, 2024

BUY
$11.58 - $17.0 $213,674 - $313,684
18,452 New
18,452 $261,000

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $259M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track This Portfolio

Track Martingale Asset Management L P Portfolio

Follow Martingale Asset Management L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

News

Stay updated on Martingale Asset Management L P with notifications on news.